Philip Morris
Passive Smoking and Coronary Artery Disease. Biological Plausibility and Severity of Effect
Fields
- Author
- Crepat, G.
- Type
- PSCI, PUBLICATION SCIENTIFIC
- ABST, ABSTRACT
- BIBL, BIBLIOGRAPHY
- CHAR, CHART, GRAPH, TABLE, MAPS
- ABST, ABSTRACT
- Area
- SCIENTIFIC AFFAIRS/BLACK LATERAL OLD S&T
- Document File
- 2023511660/2023512308/Ets: Heart Disease 930900
- Litigation
- Okag/Privilege Withdrawn
- Okag/Produced
- Characteristic
- EXTR, EXTRA
- MARG, MARGINALIA
- Site
- R529
- Named Organization
- Intl Indoor Air Quality
- Author (Organization)
- Institut Universitaire De Technologie
- Univ of Dijon
- Named Person
- Lester, J.N.
- Perry, R.
- Reynolds, G.L.
- Perry, R.
- Master ID
- 2023511661/2307
Related Documents:- 2023511661-2307 Environmental Tobacco Smoke and Heart Disease
- 2023511710 the Relationship of Passive Smoking to Various Health Outcomes Among Seventh-Day Adventists in California.
- 2023511714-1718 Passive Smoking and the Risk of Heart Attack or Coronary Death
- 2023511722-1727 Effects of Passive Smoking on Ischemic Heart Disease Mortality of Nonsmokers A Prospective Study
- 2023511728 Erratum
- 2023511729 'effects of Passive Smoking on Ischemic Heart Disease Mortality of Nonsmokers: A Prospective Study'
- 2023511730 the First Author Replies
- 2023511734-1737
- 2023511738-1744 Passive Smoking in Females and Coronary Heart Disease
- 2023511749-1756 Original Contributions Heart Disease Mortality in Nonsmokers Living with Smokers
- 2023511760-1781 Lung Cancer in Japan: Effects of Nutrition and Passive Smoking
- 2023511785-1789 Passive Smoking and Cardiorespiratory Health in A General Population in the West of Scotland
- 2023511790 Passive Smoking and Cardiorespiratory Health in Scotland
- 2023511791-1792 Passive Smoking and Cardiorespiratory Health in Scotland
- 2023511793-1795 Passive Smoking and Cardiorespiratory Health in Scotland
- 2023511800-1802 Public Health Briefs Passive Smoking and 20-Year Cardiovascular Disease Mortality Among Nonsmoking Wives, Evans County, Georgia
- 2023511806-1816 Relationship of Passive Smoking to Risk of Lung Cancer and Other Smoking-Associated Diseases
- 2023511818 Increased Incidence of Heart Attacks in Nonsmoking Women Married to Smokers
- 2023511822-1824 Cvd Epidemiology Newsletter
- 2023511829-1841 Original Contributions Effects of Passive Smoking in the Multiple Risk Factor Intervention Trial
- 2023511842 Re: 'effects of Passive Smoking in the Multiple Risk Factor Intervention Trial'
- 2023511843-1844 Re: 'effects of Passive Smoking in the Multiple Risk Factor Intervention Trial'
- 2023511845 Re: 'effects of Passive Smoking in the Multiple Risk Factor Intervention Trial'
- 2023511846 the Authors Reply
- 2023511849-1853 Smoking As A Risk Factor for Cerebral Ischemia
- 2023511857-1862 Urinary Cotinine Measurement in Patients with Buerger's Disease - Effects of Active and Passive Smoking on the Disease Process
- 2023511865-1881 An Estimate of Adult Mortality in the United States From Passive Smoking
- 2023511882 Editorial Cardiovascular Risks of Environmental Tobacco Smoke
- 2023511883-1887 An Estimate of Adult Mortality in the United States From Passive Smoking: A Response
- 2023511888-1890 An Estimate of Adult Mortality in the United States From Passive Smoking: A Response
- 2023511891-1892 Ischemic Heart Disease: Response to Lee
- 2023511893-1895 Rebuttal to Lee / Katzenstein Commentary on Passive Smoking Risk
- 2023511896-1899 An Estimate of Adult Mortality in the United States From Passive Smoking: A Response
- 2023511900-1906 An Estimate of Adult Mortality in the United States From Passive Smoking: A Response to Criticism
- 2023511908-1911 Deaths From Lung Cancer and Ischemic Heart Disease Due to Passive Smoking in New Zealand
- 2023511912 Deaths From Lung Cancer and Ischemic Heart Disease Due to Passive Smoking in New Zealand
- 2023511913 Passive Smoking in New Zealand
- 2023511914 Passive Smoking in New Zealand
- 2023511915 Passive Smoking in New Zealand
- 2023511916 Passive Smoking and Passive Thinking
- 2023511918-1937 Cardiovascular Diseases and the Work Environment A Critical Review of the Epidemiological Literature on Chemical Factors
- 2023511939-1950 Clinical Progress Series Passive Smoking and Heart Disease Epidemiology, Physiology, and Biochemistry
- 2023511952-1957 Review Passive Smoking and the Risk of Heart Disease
- 2023511958-1961 Aha Medical / Scientific Statement Position Statement Environmental Tobacco Smoke and Cardiovascular Disease A Position Paper From the Council on Cardiopulmonary and Critical Care, American Heart Association
- 2023511965-1983 the Health Consequences of Involuntary Smoking A Report of the Surgeon General
- 2023511985-1998 Environmental Tobacco Smoke Measuring Exposures and Assessing Health Effects
- 2023512000-2015 Environmental Tobacco Smoke Proceedings of the International Symposium at Mcgill University 890000 Environmental Tobacco Smoke and Cardiovascular Disease: A Critique of the Epidemiological Literature and Recommendations for Future Research
- 2023512016-2028 Panel Discussion on Cardiovascular Disease
- 2023512030-2037 Indoor Air Quality and Ventilation Environmental Tobacco Smoke (Ets) and Cardiovascular Disease
- 2023512039-2054 A Critique of the Methods Used to Assess the Toxic Effects on Man of Combustion Products.
- 2023512056-2066 Coronary Heart Disease and Involuntary Smoking
- 2023512068-2077 7. Environmental Tobacco Smoke and Coronary Heart Disease
- 2023512079-2088 Environmental Tobacco Smoke and Coronary Heart Disease
- 2023512090-2091 Editorial Give A Dog-End A Bad Name
- 2023512093-2108 Weaknesses in Recent Risk Assessments of Environmental Tobacco Smoke
- 2023512110-2129 Environmental Tobacco Smoke and Mortality A Detailed Review of Epidemiological Evidence Relating Environmental Tobacco Smoke to the Risk of Cancer, Heart Disease and Other Causes of Death in Adults Who Have Never Smoked - 5 Heart Disease
- 2023512131-2155 Environmental Tobacco Smoke Exposure and Occupational Heart Disease
- 2023512173-2180 Carbon Monoxide and Cardiovascular Disease: An Analysis of the Weight of Evidence
- 2023512185-2189 the Effects of Passive Inhalation of Cigarette Smoke on Excercise Performance
- 2023512192-2195 Effect of Passive Smoking on Angina Pectoris
- 2023512199-2202
- 2023512203-2213 Effect of 'passive' Smoking on the Physical Load Tolerance of Coronary Heart Disease Patients
- 2023512216-2220 Indoor Passive Smoking: Its Effect on Cardiac Performance
- 2023512223-2224 Passive Smoking Severely Decreases Platelet Sensitivity to Antiaggregatory Prostaglandins
- 2023512227-2230 Platelet Sensitivity to Prostacyclin in Smokers and Non-Smokers
- 2023512233-2237 Besitzen Passivraucher Ein Erhohtes Thromboserisiko?
- 2023512241-2244 Passive Smoking Affects Endothelium and Platelets
- 2023512247-2253 Lipoprotein and Oxygen Transport Alterations in Passive Smoking Preadolescent Children the Mcv Twin Study
- 2023512256-2257 Abstracts of the 30th Annual Conference on Cardiovascular Disease Epidemiology Children's Hdl-Chol: the Effects of Tobacco: Smoking, Smokeless and Parental Smoking
- 2023512261-2266 Passive Smoking Alters Lipid Profiles in Adolescents
- 2023512269-2274 Serum Lipids & Lipoprotein Profiles of Cigarette Smokers & Passive Smokers
- 2023512278-2279 8th Worldconference on Tobacco or Health Building A Tobacco-Free World 920330 - 920403 Buenos Aires - Argentina Abstracts, Posters and Videos. Serum Lipoproteins in Nonsmokers Chronically Exposed to Tobacco Smoke in the Workplace
- 2023512282 the Association Between Carotid Arterial Wall Thickness and Active and Passive Cigarette Smoking
- 2023512285 Passive Smoking and Carotid Artery Wall Thickness: the Aric Study
- 2023512290-2297 Passive Smoking Increases Experimental Atherosclerosis in Cholesterol-Fed Rabbits
- 2023512300-2301 Supplement to Circulation Abstracts From the 65th Scientific Sessions New Orleans Convention Center New Orleans, Louisiana 921116 - 921119
- 2023512304-2307 Association of Passive Smoking with Increased Coronary Heart Disease Risk Is Not Explained by Elevation of Leucocyte Count
- Date Loaded
- 24 May 1999
- UCSF Legacy ID
- yic02a00
Document Images
LQ'S ~r r a h1 .~}4,1 G,,/ 1Z2 y~:.c 16'' ~ Cl . ~- . ( .
~, 06t.r, 1~`7 Z- /, hr 4Z y- ¢4-3.
PASSSIVE SMOKING AND CORONARY
ARTERY DISEASE. BIOLOGICAL
PLAUSIBILI'TY AND SEVERITY OF
EFFEGT
G. CR$PAT
Institut Universitaire de Technologie, University of Dijon BP 510, 21014
Dijon C6dez, France
AffiIRACr
A number of small! pieces of incriminating evidence, apparently painting in
the same direction, do not neeessarily prove a crime. Therefore, before
reviewing the various mechanisms suggested to incriminate ETS in CHD'
incidence, a brief reminder oE' what is actually well known about the
atherosclerosis process is necessary. We shall stress what progress has, been
made over the last decade and what risk factors are now being considered. The
role of active smoking, which has long been set in evidence by epidemiologie
studies, is now fairly well' understood scientifically_ The mechanisms of
cardio-vascular attack are triggered by two primary stimuli: nicotine and
earbon monoxide. Induced effects on eathecholamines, platelets,
earbozyhemoglobin; frbrinogen, lipoprotein metabolism, etc... help
understand their incidence on CHD! Everything however, is not: altogether
clear nor consistent. Concerning ETS, the ten epid'emiologic studies
investigating its associatiom with heart disease mortality, produce mean RR
values ranging from 1.2 to 1.4 i,n both sexes (Glhntz). This fact and
corresponding criticisms will' not be dealt with here. We shall however
concentrate on a detailed study of the mechanisms suggested to explain the
effects of passive smoking and compare them with those of'~ active smoking. If
ETS brings into an exposed non-smoker's blood sueh primary stimuli as
nicotine, CO, benzene, PAH allow the biological plausibility of CHD attack,
but careful consideration of their mode of action and magnitude cannot, as far
as is knownincriminate ETS'as the third cause of mortality (Wells).
INTRODUCTION
There are now 10 epidemiological studies [1-10) on the relationship
between exposure to environmental tobacco smoke (ETS) in the home and the
risk of coronary heart disease (CHD) (table 1). Most of these studies have
reported relative risks greater than 11.0.
429
,,.k . -... ~,.r. t
Ail .; .-, ~

Table 1. Rel'ative risks for heart disease death from passive smoking
epidemiologic studies.
Author Type Total
cases Relative 95 96
risk confidence
interval Country
Fl.rla1CS
Hinyama (1984)'
P
494
1.2
0.9-1.4
Japan
Gillis d a!. (1984) P 21 3.6 0.9-13.8 Scotland
Garland et aG (1985) P 19 2.7 0.9-13.6 California
Leed aL (1986) C 77' 0.9 0.5-1.6 United Kingdom
Helsing et aL (1988) P 988' 1.2 1.1-1.4 Maryland
He (1989) C 34' 1.5 1.3-1.8 China
Humble d al. (1990) P 76 1.6 1.0-2.6 Georgia
Butler (1990) P 64' 1.4 0.5-3.8 California
1f7Slts
Gillis et al. (1984)
P
32
1.3
0.7-2.6
Scotland
Leed'a!. (1986) ' C 41 1.2 0.5-2.6 United Kingdom
Svendsen et ol: (1987) P 13 2.1 0.7-6.5 United States
Helsing d al. (1988) P 370 1.3 1.1-1.6 Maryland
Hok ct aL (1989) P 84 2.0 1.2-3.4 Scotland
CHD : Coronary Heart Disease P: Prospective cohort C: Case control studies
In spite of large differences in study design and type of heart disease
considered (ischaemic heart disease, death of any origin, myocardial
infarction death, non fatal coronary symptoms including angina); all
results have been pooled giving an overall relative risk estimate of 1.23
(limits 1.1-1.4) for 6 studies in women an& 1.31 (limits 1.1-1.6)~ for 4
studies in men (Wells, [11']). When these values are used to calculate CHD
mortality rate in the US:A, they give the very high figure of 32,00U deaths/year
[11i:
Glantz [12j takes up this figure an& collects evidence from a number of
more or less relevant studies all tending to prove that this finding is
plausible.
We shall first consider the formation process of atherosclerosis. It is a
complex, multifactorial slowly developing phenomenon. It is therefore
biologically plausible that ETS exposure may cause some blood factors to
vary and accelerate the atherosclerosis process. It remains to be proven,
however, that the amplitude of such variations occurring during actual ETS
ezposure produces an effect leading to a 30'b risk increase [12]. That is why,
after a brief reminder of what is known to date about the mechanism of
atherosclerosis, we shall examine what are the aggravating factors due to
active tobacco smoking: Then, we shall attempt to evaluate the impact of ETS
induced stimuli compared to those affecting an~ active smoker who is also
passively exposed to his own smoke and that of other smokers.

O1!ERVIM ON TSE' MECHANI5M
Epidemiologic studies from a variety of countries throughout the world
have clearly established a relationship between the development and/or the
progression of atherostatic process and many lifestyle factors: sedentarity,
obesity, dietary intake (excess calories, saturated fat, salt...), cholesterol,
stress, cigarette smoking... etc.
Risk factors
Since Framingham and his team published their findings 15 years ago
[13], it has been known that the three major CHD risk factors are:
hypercholesterolemia, high blood pressure and cigarette smoking (Fig. 1)
j14]. Combination of two or three of such risk factors has been found' to
increase CHD incidence nine times for two and 16 times for three factors
[14].
Figure 1. Increase in risk of coronary heart disease as a result of
smoking, hypertension and hypercholorestemia, relative to a 45-
year-old non-smoking man with a systolic blood pressure (SBP)
of 110 mm Hg and total cholesterol of 185 mg dl-1. Drawing made
on the basis of data from the Framingham study (from Kannel
W.B. [14])..
431

It is now known that some of these factors should be better defined. With
cholesterol, for instance, it is the byperlipoproteinemic anomaly which
must be considered (table 2). Cholesterol carriers such as LDL (Low Density
Lipoprotein) represent a risk and VLDL (Very Low Density Lipoprotein) an
additional risk whereas HDL (High Density Lipoprotein) counters the risk.
Apolipoproteins are better correlated with CHD risk: Apo B100 (contained in
LDL - VLDL) represent the risk, whereas Apo Al (contained in HDL)
counters the risk [15]. Bloodstream lipoproteinic particles (16) now appear
to be even more related to CHD risk. LpB or Lp(a+) [I17]I represent the risk
whereas Lp Al are the protecting agents [16]. These factors are generally of
the genetic risk type, whereas LDL modified (18) by oxidation, acetylation,
glycosylation and MDA LDL conjugation with MDA (Malondialdehyde) are
due to metabolic and environmental chemicali alterations [19,20).
Destruction of modified LDL by the "scavenger" pathway contributes through
different mechanisms to atherosclerosis development [21]. This helps
understand the aggravating effect of such oxidising substances in blood as
free radicals or the protecting role of direct' or indirect antioxydants such as
vit. C, vit. E, Se.. [22).
Table 2. Atherosclerosis and risk factors due to lipoproteinemic anomaly:
Risk increasing faetors Risk decreasing factors
Total Cholesterol *'4 Total Cholbsterol L
Cholesterol LDL Cholesterol i 1 LDLC %m
VLDL Cholesterol 7I VLDLC 1
LDL jM LDL 1
Lipoproteins VLDL *A VLDL 1
HDL 1 IiDL l
Apoproteins Apo Bi00 M Apo B100: y
Apo A1 1 Apo A1 1
4B r LpA1 J~
Lp (a+) 1~
Lipid particles o: LDL 7~
Glyc LDL q
MDA LDL 1'
other factors free radicals, etc.. Vit C, Vit E, Selenium, etc:..,
Patbogenesis of atherosclerosis
Taking into account the different theories and hypotheses on lipid
infiltration, endothelial injury, and platelet role, we can state that:
atherosclerosis is characterized by increased endothelial permeability,
monocyte infiltration, internal smooth muscle cell (SMC) proliferations
platelet aggregation and accumulation of lipids, Ca**' and extra cellular

matrix components such: as collagen, elastin an& proteoglycans in vessel
wall.
EndotJulial cell Wury (Fig. 2)'
Factors and forces promoting such damage are quite undefined and may
be of physical, metabolic, hormonal, cellular, molecular or genetic nature.
Among identifie& factors we can list: hi& blood pressure, anoxia, immune
activation, turbulent blood factors, increases in oxidized LDL, Lp(a) or free
radicals... etc. Response from irritated' endotheliaL cells induces an
increase in permeability for plasma compounds into the subendothelial
space.
HypecaDokrsiokmi.e - oxLDL
IRRCCA'IWG S'ISP7ULT Hypertemion-Ywtukntblood flov
Anozti - CO - Piee-Rad"b, et...
.
I2TiI2+1A
O
PLATELETS
AGGREGA7E
ON ENDOZfffiZIUM
SURFACE AND SECRETE :
12 HETE,IXA2, PGDF(AH)~
MEDIA
SMC:
'ContrecnBe phenotype.
sc.r (ru.) ~
MONOCYTES
infiha9on
MACROPHAGES
ACCUMULAT7ON
FOAM CELLS AND
EX7RUDED LIPIDS :
'FATTY STRP.AICS'
~
LESION GROWS :
SMC PROLIFERA77ON
COLLAGEN SECRETTON
ELAS'PiN',PROTEOLYCAN,
GLYCOAMINOGLYCAN,
CHOLES'lEROTL azd C...
Qeposleon
Figure 2. Pathogenesis of atherosclerosis.
433
LDL
OXLDL
Lp(a)
,cn: (vis)
u
SMC
PROLIFERA'IiON
'Synmetic pAenatqpe

lnfUtrotion of plaima components (PiQ. 2)
Endothelial injury enhances infiltration of monocytes which
differentiate into macrophages, LDL and possibly Lp(a) which are oxidized
by damaged endothelial cells [27J1 Macrophages and oxidized LDL are
chemostatic for monoeytes which further penetrate into subendothelial space
[22].
:'1'3tEE`-~AIlTCkLiz?`::
j O= 2RA1tSPOrrr
t ooM
PC2t - TXAz 8 AL"CE
I
PLA7ZLFf AOaRLOA7iON
CB2C[TLAnNa
t CATECHOiAMINES
t!!A tLDL 1FDL
t MONOClZB
WFII.IRAI7ON
~
,t MAi3ROPHAdEB
i
=MC,DDORAY7ON
PROL!l132A7ION
WPLUX LDL
EPlLUDC HDL
EALANCE
t OX LDL
T
A'IFIFROSCLPROSiS
Figure 3. Smoking, CO, Nicotine, free radicals, PARs and
atherosclerosis.
Foam cell'accamulation and platelet aggregation (Fig: 2)
The modified LDLs are taken up via the scavenger receptor pathway by
macrophages which turn into foam cells [21,231. Continued accumulation of
macrophages in the presence of high cholesterol leads to extrusion of lipids
into the arterial wall interstitial space and formation of the "fatty streak"
which has become one of the pathological hallmarks of the atherosclerotic
process.
Several more or less known factors cause platelets to adhere to the
injured endothelium. Macrophages and platelets release growth factors
434

PGDF(AB) from platelets and PGDF(BB) from macrophages (Heldin) [25]
which are chemostatic and mitogenic for vascular smooth muscle cells.
Vascular SMC are assumed'to migrate from the media to the intima where
they convert from a contractile into a synthetic phenotype, proliferate and
secrete growth factors (PGDFAA) [26]. At this stage, we must stress the
importance of the balance between prostacycline (PG12) secreted by injured
endothelial cells which inhibits platelet aggregation and thromboxane
(TXA2) secreted by the platelets which stimulates aggregation [27].
Progression of atherosclerosis (Fig. 2)
The hallmark in the progression of atherosclerosis is the proliferation
of SMC and accumulation of extra cellular matrix in the intimal layer:
collagen, elastin, proteoglpcans (PGs), glycoaminoglyeans (GAGs). These
molecules combine with LDL, modified LDL, Lp(a); celli debris, Ca++
deposits to form, an atheroma gradually weakening and narrowing the artery,
encouraging the formation of a thrombus which may develop into myocardiali
infarction.
Finally, there is normally a balance between cholesterol influx (LDL,
Lp(a) into the membrane and cholesterol efflux (HDL2) out of the plasma
membrane. When influx of cholesterol! exceeds efflux, cholesterylesters
are stored by the cells. On the ot'her hand, the lesion progression is also
dependent on SMC proliferation and consequently on the balance between
growth promoters (PGDF; TXA2, 12 HETE) and growth inhibitors (PGI2).
This is just an overview of atherosclerosis pathogenesis which does not
cover the abundant literature documenting such factors as :
Lipoperoxydation of polyunsaturated fatty acids leading to MDA-LDL
[181;
Free radicals and antioxidising role of plasma [28] selenium,
The role of Ca++ as a second messenger involved in regulating processes
in the vessel wall [27] promoting LDL receptor binding, inducing
monocyte and SMC chemotaxis and stimulating secretion of collagen
and other components.
A number of epidemiologic studies have brought evidence of association
between active smoking and atherosclerosis development but the physio-
biochemical mechanisms suggested are not yet definite as many smoke
constituents are likely to be involved.
Mainstream smoke chemical compwaition
About 4,000 components have been identified in mainstream smoke. In
the gas phase the major constituents are: carbon dioxide, carbon monoxide,
435

nitrogen oxides, nitrosocompounds, hydrogen cyanide, formaldehyde,
PAH and free radicals have also been investigated.
atherosclerosis development are nicotine carbon monoxide (CO) [54], while
specific chemical substance. The primary stimuli involved in
using all mainstream smoke or tars, which cannot lead to incriminate any
A number of investigations of smoke toxicity have been carried out in
found in the particulate phase: nicotine, phenol, benzo(a)pyrene,
nitrosamines, pyrene, naphtalene, etc...
acrolein and benzene. The biologically active compounds, however, are
prostanoid synthesis PG12-TXA2 by decreasing PGI2 synthesis by vascular
endothelial cells [38], increasing release of TXA2 platelets [40] an&
incidentally platelet' aggregation and SMC constriction. In fact, the direct
role of nicotine and its action as a function of dose and in presence of CO iss
still controversial [41).
6. Carbon monoxide: Carbon monoxide forms carboxyhaemoglobin;
reduces blood oxygen-carrying capacity and causes hypoxemia. Mean COHb
Lipid(s)) which cause LDL oxidation and then pathogenesis of smoking-
induced atherosclerosis [37]..
5. PGI2-TXA2 Balance: Cigarette-smoking affects the balance of vascular
smoking induces increased PAF-LL (PlateleU-Activating-Factor-Like-
which can produce the same effect in vitro. On the other hand, cigarette
platelet aggregabili'ty [35, 36] The responsible agent is likely to be nicotine
4. Platelets: Cigarette smoking induces a marked,, transient increase in
reversed in just 30 days after cessation of smoking (Moffsat R.) (33).
smoking on HDL cholesterol does not seem to be cumulative and cam be
correlates positively with HDL cholesterol subfraction. Finally, the effect of
decrease associated with cigarette smoking. Alcohol consumption, however,
controversial and recent studies [34]' Snd' no statistically significant HDL
fraction [33]. The data on association between CHD and HDL subfraction is
HDL tend to be lower and LDL slightly elevated. The most important aspect
could be the sharp decrease in the anti-atherogenic HDL2 cholesterol
Lipoproteins: a number of studies have shown that in smokers' plasma
heart and therefore increases oxygen consumption [32].
sympathoadrenal stimulation [31] : but increases the delivery of FFA to the
lipolysis. FFA mobilisation from adipose tissue is a consequence of
injected nicotine raises plasma concentration of FFA through enhanced
3. Effects on lipids: Increase in free fatty acids (FFA): intravenously
myocardial contractile function [30],.
explained by direct action of nicotine or by cathecol6mine action on
2. Increase in blood pressure and heart'rate: this effect can be readily
adrenal glands or cardiac tissues [521.
increase sympathetic nervous activity and': release catecholamines from
1. Nicotine alone or in conjunction with cigarette smoking is known~ to
Maiastream smoke (MS) stimuli (k}g. 3)
436

levels in smokers are about 5 % but may reach 10 % and more in heavy
smokers. CO can affect permeability of endothelial wall, fibrinogen
retention by arterial wall and PGIZ-TXA2 balance [41J.
7. Polycyclic Aromatic Hydrocarbons (PAHs): By weekly PAH injections
in pectoral muscles of white carneau pigeons, Revis [42) showed that PAH
such as Benzo(a)' pyrene (BaP) with the exclusion of BeP, might be the only
potential atherogen in avian atherosclerosis. Randerath [43J also
demonstrated on mice dermally treated with cigarette tar presumably
containing aromatic compounds like BaP, induced lesions in heart DNA in a
tissue specific manner. However, the administration route, the doses and
the species, cannot convincingly lead to the conclusion that it is an
atherosclerosis risk for a smoker.
8. Free radicals: We know that smoke contains free radicals and that free
radicals are found in the atheroma plaque. Free radicals have been,
implicated in cardiac ischaemic artery [44] and congestive heart failure
[451. Free radicals can cause lipoperoxidation of unsaturated fatty acids and
then form MDA (Malondialdehyde). LDL malonisation, then leads to
increased fixation on macrophages with foam cell' production [57).
1
To sum up (Fig. 3); consistent evidence is now available to explain the
aggravating effect of tobacco smoke on atheroma plaque. Nicotine and
carbon monoxide are the identified primary stimuli causing a chain of
biochemical reactions accelerating the atherosclerosis process [54]. Free
radicals and polycyclic aromatic hydroxarbons are among the molecules
recently incriminated but their precise role and mode of action require
further investigation.
A AND PASSIVE SMOHIIVG
ETS exposure has no marked effects on atherosclerosis parameters.
This is due to the fact that amounts of active compounds which penetrate into
the body are on the whole very small even for heavy exposures, as is most
convincingly demonstrated by Scherer [46) (Table 3). The findings provide
experimental evidence that for passive smoking, exposure to the gas phase of
ETS is more important' than to the particulate phase. In contrast to smoking,
uptake of tobacco smoke derived particles during passive smoking seems to
be very low and not detectable by usual methods [46]! Therefore, nicotine and
cotinine in smokers reflect smoke particle exposure whereas in passivee
smokers these parameters indicate exposure mainly to tobacco smoke
vapour phase.
Let us consider the blood stimuli generated by ETS, likely to contribute to
atherosclerosis process.
co.ooHb
As Carbon monoxide is mainly a vapour phase compound of sidestream.
437

Table 3. Estimated dose ratio between smoking and passive smoking
from G. Scherer [46].
Tobacco smoke constituents Smoking S
(20 eig/d)i Passive smoking
PS (81Jd)~ Doae ratio
SJPS
V-Phase
CO (mg)
40-400'
14.4-96
2.7-4.2
Volatile nitrosamines (ug) 0.05-1.0 0.03-0.4' 1.5-2,6
Benzene (ug) 200-1200 40-400 3-5
Particulabe matter
Particles (mg)
75-300
0:024-0.24
1250-3000
Nicotine (mg) 7.5-30 0:08-0.4 7590
Benzo(a)-pyrene (ug) 0.15-0.75 OA01,0.011 75-150
Tobaccospecific nitrosamines (ug) 4.5-45 0.002-0:010 2300-4500
smoke, an exposed non-smoker shows a significant increase in CoHb after
heavy ETS exposure. However, CO uptake is 2.7 to 4.2 times lower than in an
active smoker (table 3) [46] CoHb levelk obtained range from 0.5 to 1.5%
(National Research Council 81, Aronow 78, Wald 81 [47], Davis [48]; though
Sherer [46] found a higher CoHb value 6 % after 8 hours''exposure. In fact, 1%.
CoHb is considered to be representative of average tobacco smoke exposures,,
which is not far from levels observed in exposures to other CO sources:
cooking, heating, exhaust fumes, etc... (3 % CoHb in non-smoking taxi
drivers in London): In active smokers, however, CoHb levels are much
higher: 5% and more. Moskowitz [47] found that whole blood 2-3
diphosphoglycerate (2-3 DPG) was higher in~ smoke-exposed than in
unexposed' children, which shows that the organism attempts to compensate
for hypoxia by increasing 2-3 DPG level in blood' to meet tissue oxygen
requirements. However, the results are significant for boys only.
Nicotine
In a non-smoker, plasma nicotine rises so faintly after exposure to
tobacco smoke that' variations observed are sometimes not significant.
Regarding significant quantities absorbed, Sherer [46] has recently shown
(table 3) that an active smoker's (S) uptake is 75 to 90 times that of a passive
smoker (PS). Regarding plasma, salivary or urinary concentrations, Jarvis
[49]ihas found that the ratio is about 100. I'n these circumstances, direct or
indirect action of nicotine on an ETS expose& non smoker can only be very
weak.
Lipids
Only a few studies have investigated this aspect. Moskovit'z [47] found
that High Density Lipoprot'ein (HDL) cholesterol' was lower in ETS expose&
children ; the HDL2 cholesterol subfraotion was decreased but in boys only
438'
